Citi Initiates Coverage on Nektar with Buy Rating, Launches 'Positive Catalyst Watch'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy NKTR?
Citi's Coverage Initiation: Citi has initiated coverage of Nektar with a Buy rating and a price target of $102.
Positive Catalyst Watch: The firm has placed Nektar on a "positive 90-day catalyst watch" in anticipation of Phase 2b alopecia areata data expected in December.
Competitive Data Outlook: Citi believes that the data for rezpegaldesleukin in atopic dermatitis appears competitive within a crowded market.
Investment Opportunity: The firm sees an "asymmetrical upside" opportunity for Nektar's shares leading up to the December data readout.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 85.040
Low
102.00
Averages
123.43
High
165.00
Current: 85.040
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On April 20, 2026, Nektar granted 28,450 stock options and 2,950 restricted stock units (RSUs) to six new employees, indicating the company's proactive approach to talent acquisition aimed at strengthening its team to support future R&D efforts.
- Incentive Plan Background: This grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, which is exclusively for granting equity awards to new hires, aligning with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting talent.
- Option Terms Details: The stock options have an exercise price of $100.35 per share, equal to the closing price on the grant date, with an eight-year term and vesting over four years, reflecting the company's recognition and motivation for long-term employee contributions.
- RSU Vesting Arrangement: The RSUs also vest over four years, with 1/4 vesting after the first year and 1/16 vesting quarterly thereafter, ensuring employees remain with the company to receive their rewards, thereby enhancing employee loyalty and sense of belonging.
See More
Class Action Filed Against Nektar Therapeutics
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, indicating significant legal risks for the company.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly negatively impact trial results, revealing potential operational and compliance failures within the company.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, emphasizing the proactive role investors can take in legal proceedings.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is nationally recognized for representing investors in securities fraud class actions, having recovered hundreds of millions of dollars for investors nationwide, showcasing its strength and credibility in the legal field.
See More
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the litigation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially causing investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and resource advantages in this field.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26 and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements.
- Investor Losses: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, affecting investor decision-making.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit for compensation, noting that the class has not yet been certified, meaning absent shareholders are not legally represented.
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating Nektar Therapeutics for potential claims, encouraging investors who purchased securities between February 26, 2025, and December 15, 2025, to reach out and discuss their legal options, highlighting the firm's commitment to investor rights.
- Class Action Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek lead plaintiff status in a federal securities class action against Nektar, emphasizing the importance of timely action to protect their legal interests.
- Potential Claim Risks: As the investigation progresses, investors may have opportunities to file claims for losses, indicating that the company may have undisclosed risks or issues affecting its stock price and market confidence.
- Direct Contact Channels: Investors can directly contact Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information and to discuss their legal rights, ensuring their voices are heard.
See More
Nektar Therapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: Nektar Therapeutics is facing a securities fraud class action lawsuit alleging that its executives made false statements regarding the Phase 2b trial for REZOLVE-AA between February 26 and December 15, 2025, potentially leading to investor losses.
- Investor Action: Affected investors must file papers by May 5, 2026, to serve as lead plaintiffs in the class action; those who choose not to act will remain absent class members and may miss out on any potential recovery.
- Legal Fees: Bernstein Liebhard LLP operates on a contingency fee basis, meaning investors incur no fees or expenses, thereby reducing the financial risk of participating in the lawsuit.
- Law Firm Background: Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for clients and has a strong reputation in handling class actions, having been named to The National Law Journal’s “Plaintiffs’ Hot List” multiple times.
See More
Nektar Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On April 20, 2026, Nektar granted 28,450 stock options and 2,950 restricted stock units (RSUs) to six new employees, indicating the company's proactive approach to talent acquisition aimed at strengthening its team to support future R&D efforts.
- Incentive Plan Background: This grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, which is exclusively for granting equity awards to new hires, aligning with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting talent.
- Option Terms Details: The stock options have an exercise price of $100.35 per share, equal to the closing price on the grant date, with an eight-year term and vesting over four years, reflecting the company's recognition and motivation for long-term employee contributions.
- RSU Vesting Arrangement: The RSUs also vest over four years, with 1/4 vesting after the first year and 1/16 vesting quarterly thereafter, ensuring employees remain with the company to receive their rewards, thereby enhancing employee loyalty and sense of belonging.
See More
Class Action Filed Against Nektar Therapeutics
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, indicating significant legal risks for the company.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly negatively impact trial results, revealing potential operational and compliance failures within the company.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, emphasizing the proactive role investors can take in legal proceedings.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is nationally recognized for representing investors in securities fraud class actions, having recovered hundreds of millions of dollars for investors nationwide, showcasing its strength and credibility in the legal field.
See More
Reminder of Class Action Lawsuit for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the litigation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially causing investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and resource advantages in this field.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26 and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial in its public statements.
- Investor Losses: As the market learned the truth about Nektar, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, affecting investor decision-making.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit for compensation, noting that the class has not yet been certified, meaning absent shareholders are not legally represented.
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating Nektar Therapeutics for potential claims, encouraging investors who purchased securities between February 26, 2025, and December 15, 2025, to reach out and discuss their legal options, highlighting the firm's commitment to investor rights.
- Class Action Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek lead plaintiff status in a federal securities class action against Nektar, emphasizing the importance of timely action to protect their legal interests.
- Potential Claim Risks: As the investigation progresses, investors may have opportunities to file claims for losses, indicating that the company may have undisclosed risks or issues affecting its stock price and market confidence.
- Direct Contact Channels: Investors can directly contact Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information and to discuss their legal rights, ensuring their voices are heard.
See More
Nektar Therapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: Nektar Therapeutics is facing a securities fraud class action lawsuit alleging that its executives made false statements regarding the Phase 2b trial for REZOLVE-AA between February 26 and December 15, 2025, potentially leading to investor losses.
- Investor Action: Affected investors must file papers by May 5, 2026, to serve as lead plaintiffs in the class action; those who choose not to act will remain absent class members and may miss out on any potential recovery.
- Legal Fees: Bernstein Liebhard LLP operates on a contingency fee basis, meaning investors incur no fees or expenses, thereby reducing the financial risk of participating in the lawsuit.
- Law Firm Background: Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for clients and has a strong reputation in handling class actions, having been named to The National Law Journal’s “Plaintiffs’ Hot List” multiple times.
See More
